To date, only one of the very few FDA-approved ccfDNA-based tests with clinical utility is the Cobas® EGFR Mutation Test v2 (Roche Molecular Systems Inc., Pleasanton, CA, USA) detecting 42 EGFR hotspot mutations in ccfDNA from patients with lung cancer [5,18,19,20,21,22]. The gene discussed is EGFR; the disease is lung carcinoma.